In our pursuit to determine whether FGFR2 mutations could increase the therapeutic sensitivity of ICC cells, we employed human cholangiocarcinoma RBE cells as a model system and infected them with lentiviruses expressing a range of FGFR2 mutations. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.